American Journal of Transplantation · 2017 · 133 citations · 22 references
Life SciencesImmunologyNephrologyKidney TransplantationTransplant ImmunologyTransplant SurgeryAntibody-mediated RejectionDonor-specific AntibodiesGraft SurvivalImmunosuppression In Kidney TransplantationImmunosuppressive TherapyTransplant RejectionKidney Transplant ImmunosuppressionOptimal Dose SelectionPreexisting Donor-specific AntibodiesRenal Transplant RejectionTacrolimus ExposureTacrolimus TherapyTherapeutic Dose OptimizationTherapeutic Dose Range
De novo donor-specific antibodies (dnDSAs) have been associated with reduced graft survival. Tacrolimus (TAC)–based regimens are the most common among immunosuppressive approaches used in in clinical practice today, yet an optimal therapeutic dose to prevent dnDSAs has not been established. We evaluated mean TAC C0 (tacrolimus trough concentration) and TAC time in therapeutic range for the risk of dnDSAs in a cohort of 538 patients in the first year after kidney transplantation. A mean TAC C0 < 8 ng/mL was associated with dnDSAs by 6 months (odds ratio [OR] 2.51, 95% confidence interval [CI] 1.32–4.79, P = .005) and by 12 months (OR 2.32, 95% CI 1.30–4.15, P = .004), and there was a graded increase in risk with lower mean TAC C0. TAC time in the therapeutic range of <60% was associated with dnDSAs (OR 2.05, 95% CI 1.28-3.30, P = .003) and acute rejection (hazard ratio [HR] 4.18, 95% CI 2.31–7.58, P < .001) by 12 months and death-censored graft loss by 5 years (HR 3.12, 95% CI 1.53–6.37, P = .002). TAC minimization may come at a cost of higher rates of dnDSAs, and TAC time in therapeutic range may be a valuable strategy to stratify patients at increased risk of adverse outcomes. De novo donor-specific antibodies (dnDSAs) have been associated with reduced graft survival. Tacrolimus (TAC)–based regimens are the most common among immunosuppressive approaches used in in clinical practice today, yet an optimal therapeutic dose to prevent dnDSAs has not been established. We evaluated mean TAC C0 (tacrolimus trough concentration) and TAC time in therapeutic range for the risk of dnDSAs in a cohort of 538 patients in the first year after kidney transplantation. A mean TAC C0 < 8 ng/mL was associated with dnDSAs by 6 months (odds ratio [OR] 2.51, 95% confidence interval [CI] 1.32–4.79, P = .005) and by 12 months (OR 2.32, 95% CI 1.30–4.15, P = .004), and there was a graded increase in risk with lower mean TAC C0. TAC time in the therapeutic range of <60% was associated with dnDSAs (OR 2.05, 95% CI 1.28-3.30, P = .003) and acute rejection (hazard ratio [HR] 4.18, 95% CI 2.31–7.58, P < .001) by 12 months and death-censored graft loss by 5 years (HR 3.12, 95% CI 1.53–6.37, P = .002). TAC minimization may come at a cost of higher rates of dnDSAs, and TAC time in therapeutic range may be a valuable strategy to stratify patients at increased risk of adverse outcomes.
22
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
F.R. Rosendaal, Suzanne C. Cannegieter, F.J.M. van der Meer et al. · Thrombosis and Haemostasis · 1993 · 2.1K citations · Full text
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Henrik Ekberg, Hélio Tedesco‐Silva, A. Demirbaş et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text